R3TA (the "Triple G") is the first drug to target three metabolic receptors simultaneously.
• Maximum Weight Loss: It currently holds the record for efficacy, with clinical trials showing up to 28.7% total body weight loss over 68 weeks.
• Triple-Action Mechanism: It combines appetite suppression (GLP-1/GIP) with a metabolic boost (Glucagon) that increases energy expenditure and fat breakdown.
• Liver Health: It is exceptionally potent at clearing liver fat, making it a leading candidate for treating fatty liver disease (MASH).
• Blood Sugar Control: It significantly lowers A1C levels and improves insulin sensitivity in patients with Type 2 Diabetes.
• Cardiovascular Health: Leads to marked improvements in blood pressure, cholesterol, and inflammation markers.